“Keaping” a lid on lung cancer: the Keap1-Nrf2 pathway

References

• Fitzmaurice C, Allen C, Rm B, et al.; Global Burden of Disease Cancer C. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–548.
   PubMed Web of Science ®Google Scholar
• George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47–53.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–525.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–550.
   PubMed Web of Science ®Google Scholar
• Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci. 2014;39:199–218.
   PubMed Web of Science ®Google Scholar
• Best SA, De Souza DP, Kersbergen A, et al. Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment. Cell Metab. 2018;27:935–43 e4.
   PubMed Web of Science ®Google Scholar
• Romero R, Sayin VI, Davidson SM, et al. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med. 2017;23:1362–1368.
   PubMed Web of Science ®Google Scholar
• Chen W, Sun Z, Wang X-J, et al. Direct interaction between Nrf2 and p21 Cip1/WAF1 upregulates the Nrf2-mediated antioxidant response. Mol Cell. 2009;34:663–673.
   PubMed Web of Science ®Google Scholar
• Komatsu M, Kurokawa H, Waguri S, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol. 2010;12:213.
   PubMed Web of Science ®Google Scholar
• Lau A, Wang X-J, Zhao F, et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol. 2010;30:3275–3285.
   PubMed Web of Science ®Google Scholar
• Salazar M, Rojo AI, Velasco D, et al. Glycogen synthase kinase-3β inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem. 2006;281:14841–14851.
   PubMed Web of Science ®Google Scholar
• Joo MS, Kim WD, Lee KY, et al. AMPK facilitates nuclear accumulation of Nrf2 by phosphorylating at serine 550. Mol Cell Biol. 2016;36:1931–1942.
   PubMed Web of Science ®Google Scholar
• Alexander C-M. The involvement of NRF2 in lung cancer. Oxid Med Cell Longev. 2013;2013.
   Web of Science ®Google Scholar
• Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013;27:2179–2191.
   PubMed Web of Science ®Google Scholar
• Lee SB, Sellers BN, DeNicola GM. The Regulation of NRF2 by Nutrient-Responsive Signaling and Its Role in Anabolic Cancer Metabolism. Antioxid Redox Signal. 2017 Oct 16.
   Web of Science ®Google Scholar
• Menegon S, Columbano A, Giordano S. The dual roles of NRF2 in cancer. Trends Mol Med. 2016;22:578–593.
   PubMed Web of Science ®Google Scholar
• Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci. 2009;34:176–188.
   PubMed Web of Science ®Google Scholar
• Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. 2012;12:564.
   PubMed Web of Science ®Google Scholar
• Padmanabhan B, Tong KI, Ohta T, et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell. 2006;21:689–700.
   PubMed Web of Science ®Google Scholar
• Ohta T, Iijima K, Miyamoto M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 2008;68:1303–1309.
   PubMed Web of Science ®Google Scholar
• Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006;3:e420.
   PubMed Web of Science ®Google Scholar
• Canning P, Sorrell FJ, Bullock AN. Structural basis of Keap1 interactions with Nrf2. Free Radic Biol Med. 2015;88:101–107.
   PubMed Web of Science ®Google Scholar
• Campbell JD, Alexandrov A, Kim J, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016;48:607–616.
   PubMed Web of Science ®Google Scholar
• Frank R, Scheffler M, Merkelbach-Bruse S, et al. Clinical and Pathological Characteristics of KEAP1-and NFE2L2-Mutated Non–small Cell Lung Carcinoma (NSCLC). Clin Cancer Res. 2018: 24:3087-3096.
   PubMedGoogle Scholar
• Luo W, Tian P, Wang Y, et al. Characteristics of genomic alterations of lung adenocarcinoma in young never‐smokers. International Journal of Cancer. 2018 Apr 18.
   Web of Science ®Google Scholar
• George J, Walter V, Peifer M, et al. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun. 2018;9:1048.
   PubMed Web of Science ®Google Scholar
• Mollaoglu G, Guthrie MR, Böhm S, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition. Cancer Cell. 2017;31:270–285.
   PubMed Web of Science ®Google Scholar
• Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018;173(321–37):e10.
   Google Scholar
• Kim YR, Oh JE, Kim MS, et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol. 2010;220:446–451.
   PubMed Web of Science ®Google Scholar
• Wakabayashi N, Itoh K, Wakabayashi J, et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet. 2003;35:238–245.
   PubMed Web of Science ®Google Scholar
• Shibata T, Ohta T, Tong KI, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci. 2008; 105:13568–13573.
   Google Scholar
• Kwon M-C, Berns A. Mouse models for lung cancer. Mol Oncol. 2013;7:165–177.
   PubMed Web of Science ®Google Scholar
• Blake DJ, Singh A, Kombairaju P, et al. Deletion of Keap1 in the lung attenuates acute cigarette smoke-induced oxidative stress and inflammation. Am J Respir Cell Mol Biol. 2010;42:524–536.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Byers LA, Diao L, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5:860–877.
   PubMed Web of Science ®Google Scholar
• Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15:3243–3248.
   PubMed Web of Science ®Google Scholar
• DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc. 2009;4:1064–1072.
   PubMed Web of Science ®Google Scholar
• Jackson EL, Olive KP, Tuveson DA, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005;65:10280–10288.
   PubMed Web of Science ®Google Scholar
• Winslow MM, Dayton TL, Verhaak RG, et al. Suppression of lung adenocarcinoma progression by Nkx2–1. Nature. 2011;473:101.
   PubMed Web of Science ®Google Scholar
• Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007;448:807.
   PubMed Web of Science ®Google Scholar
• Li F, Han X, Li F, et al. LKB1 inactivation elicits a redox imbalance to modulate non-small cell lung cancer plasticity and therapeutic response. Cancer Cell. 2015;27:698–711.
   PubMed Web of Science ®Google Scholar
• Rogers ZN, McFarland CD, Winters IP, et al. A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. Nat Methods. 2017;14:737.
   PubMed Web of Science ®Google Scholar
• Rogers ZN, McFarland CD, Winters IP, et al. Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice. Nat Genet. 2018;50:483-486.
   Web of Science ®Google Scholar
• Sánchez-Rivera FJ, Papagiannakopoulos T, Romero R, et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature. 2014;516:428.
   PubMed Web of Science ®Google Scholar
• Mitsuishi Y, Taguchi K, Kawatani Y, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012;22:66–79.
   PubMed Web of Science ®Google Scholar
• Taguchi K, Hirano I, Itoh T, et al. Nrf2 enhances cholangiocyte expansion in Pten-deficient livers. Mol Cell Biol. 2014;34:900–913.
   PubMed Web of Science ®Google Scholar
• Weeden CE, Chen Y, Ma SB, et al. Lung Basal Stem Cells Rapidly Repair DNA Damage Using the Error-Prone Nonhomologous End-Joining Pathway. PLoS Biol. 2017;15:e2000731.
   PubMed Web of Science ®Google Scholar
• Sutherland KD, Proost N, Brouns I, et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell. 2011;19:754–764.
   PubMed Web of Science ®Google Scholar
• Sutherland KD, Song JY, Kwon MC, et al. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. Proc Natl Acad Sci U S A. 2014;111:4952–4957.
   PubMed Web of Science ®Google Scholar
• Sutherland KD, Berns A. Cell of origin of lung cancer. Mol Oncol. 2010;4:397–403.
   PubMed Web of Science ®Google Scholar
• Jeong Y, Hoang NT, Lovejoy A, et al. Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance. Cancer Discov. 2017;7:86–101.
   PubMed Web of Science ®Google Scholar
• Ferone G, Song JY, Sutherland KD, et al. SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin. Cancer Cell. 2016;30:519–532.
   PubMed Web of Science ®Google Scholar
• Best SA, Kersbergen A, Asselin-Labat ML, et al. Combining Cell Type-Restricted Adenoviral Targeting with Immunostaining and Flow Cytometry to Identify Cells-of-Origin of Lung Cancer. Methods Mol Biol. 2018;1725:15–29.
   PubMedGoogle Scholar
• Borthwick DW, Shahbazian M, Todd Krantz Q, et al. Evidence for stem-cell niches in the tracheal epithelium. Am J Respir Cell Mol Biol. 2001;24:662–670.
   PubMed Web of Science ®Google Scholar
• Parsons DW, Grubb BR, Johnson LG, et al. Enhanced in vivo airway gene transfer via transient modification of host barrier properties with a surface-active agent. Hum Gene Ther. 1998;9:2661–2672.
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Yin X, Hoadley KA, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2010;16:4864–4875.
   PubMed Web of Science ®Google Scholar
• Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41:1238–1242.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Berrett KC, Kc U, et al. Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer. Cell Rep. 2014;8:40–49.
   PubMed Web of Science ®Google Scholar
• Han X, Li F, Fang Z, et al. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat Commun. 2014;5:3261.
   PubMed Web of Science ®Google Scholar
• Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519.
   PubMedGoogle Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–1033.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Sivridis E, Arelaki S, et al. Expression of enzymes related to glucose metabolism in non-small cell lung cancer and prognosis. Exp Lung Res. 2017;43:167–174.
   PubMed Web of Science ®Google Scholar
• DeNicola GM, Chen PH, Mullarky E, et al. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet. 2015;47:1475–1481.
   PubMed Web of Science ®Google Scholar
• Singh A, Happel C, Manna SK, et al. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest. 2013;123:2921–2934.
   PubMed Web of Science ®Google Scholar
• Boros LG, Puigjaner J, Cascante M, et al. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res. 1997;57:4242–4248.
   PubMed Web of Science ®Google Scholar
• Amelio I, Cutruzzolá F, Antonov A, et al. Serine and glycine metabolism in cancer. Trends Biochem Sci. 2014;39:191–198.
   PubMed Web of Science ®Google Scholar
• Sayin VI, LeBoeuf SE, Singh SX, et al. Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer. eLife. 2017 Oct 2;6. e28083.
   PubMed Web of Science ®Google Scholar
• Solis LM, Behrens C, Dong W, et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2010;16:3743–3753.
   PubMed Web of Science ®Google Scholar
• Bai X, Chen Y, Hou X, et al. Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug Metab Rev. 2016;48:541–567.
   PubMed Web of Science ®Google Scholar
• McDonald J, Kim K, Norris A, et al. Ionizing radiation activates the Nrf2 antioxidant response. Cancer Res. 2010;70:8886–8895.
   PubMed Web of Science ®Google Scholar
• Krall EB, Wang B, Munoz DM, et al. KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. eLife. 2017 Feb 1;6. e18970.
   Web of Science ®Google Scholar
• Ji L, Li H, Gao P, et al. pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PloS One. 2013;8:e63404.
   PubMed Web of Science ®Google Scholar
• Munoz M, Henderson M, Haber M, et al. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life. 2007;59:752–757.
   PubMed Web of Science ®Google Scholar
• Berger W, Setinek U, Hollaus P, et al. Multidrug resistance markers p-gp, MRP1 and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol. 2005;131:355–363.
   PubMed Web of Science ®Google Scholar
• Hsia T-C, Lin -C-C, Wang -J-J, et al. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. Lung. 2002;180:173–179.
   PubMed Web of Science ®Google Scholar
• No J, Kim Y, Song Y. Targeting nrf2 signaling to combat chemoresistance. J Cancer Prev. 2014;19:111–117.
   PubMedGoogle Scholar
• Ren D, Villeneuve NF, Jiang T, et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci. 2011;108:1433–1438.
   PubMed Web of Science ®Google Scholar
• Arlt A, Sebens S, Krebs S, et al. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene. 2013;32:4825.
   PubMed Web of Science ®Google Scholar
• Tarumoto T, Nagai T, Ohmine K, et al. Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line. Exp Hematol. 2004;32:375–381.
   PubMed Web of Science ®Google Scholar
• Gao A-M, Ke Z-P, Shi F, et al. Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Chem Biol Interact. 2013;206:100–108.
   PubMed Web of Science ®Google Scholar
• Gao A-M, Ke Z-P, Wang J-N, et al. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis. 2013;34:1806–1814.
   PubMed Web of Science ®Google Scholar
• Tang X, Wang H, Fan L, et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med. 2011;50:1599–1609.
   PubMed Web of Science ®Google Scholar
• Singh A, Venkannagari S, Oh KH, et al. Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors. ACS Chem Biol. 2016;11:3214–3225.
   PubMed Web of Science ®Google Scholar
• Bollong MJ, Yun H, Sherwood L, et al. A small molecule inhibits deregulated NRF2 transcriptional activity in cancer. ACS Chem Biol. 2015;10:2193–2198.
   PubMed Web of Science ®Google Scholar
• Mullarky E, Lucki NC, Beheshti Zavareh R, et al. Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proc Natl Acad Sci U S A. 2016;113:1778–1783.
   PubMed Web of Science ®Google Scholar
• McMillan EA, Ryu M-J, Diep CH, et al. Chemistry-first approach for nomination of personalized treatment in lung cancer. Cell. 2018;173(864–78):e29.
   Google Scholar
• Chalmers Z, Connelly C, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9(1):34.
   Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–128.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non–small-Cell Lung Cancer. New England J Med. 2018;378(22):2078-2092.
   Web of Science ®Google Scholar
• Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355–1363.
   PubMed Web of Science ®Google Scholar
• Pfirschke C, Engblom C, Rickelt S, et al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity. 2016;44:343–354.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(812–30):e14.
   Google Scholar